Tuberous sclerosis complex–associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Tuberous sclerosis complex (TSC) is a dominantly inherited disease caused by hyperactivation of the mTORC1 pathway and characterized by the development of hamartomas and benign tumors, including in the brain. Among the neurological manifestations associated with TSC, the tumor progression of static subependymal nodules (SENs) into subependymal giant cell astrocytomas (SEGAs) is one of the major causes of morbidity and shortened life expectancy. To date, mouse modeling has failed in reproducing these 2 lesions. Here we report that simultaneous hyperactivation of mTORC1 and Akt pathways by codeletion of Tsc1 and Pten, selectively in postnatal neural stem cells (pNSCs), is required for the formation of bona fide SENs and SEGAs. Notably, both lesions closely recapitulate the pathognomonic morphological and molecular features of the corresponding human abnormalities. The establishment of long-term expanding pNSC lines from mouse SENs and SEGAs made possible the identification of mTORC2 as one of the mediators conferring tumorigenic potential to SEGA pNSCs. Notably, in spite of concurrent Akt hyperactivation in mouse brain lesions, single mTOR inhibition by rapamycin was sufficient to strongly impair mouse SEGA growth. This study provides evidence that, concomitant with mTORC1 hyperactivation, sustained activation of Akt and mTORC2 in pNSCs is a mandatory step for the induction of SENs and SEGAs, and, at the same time, makes available an unprecedented NSC-based in vivo/in vitro model to be exploited for identifying actionable targets in TSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, the pharmacokinetics of NV-5138 in rodents is relatively short (~3 hours) and the extent of mTORC1 activation is limited (2- to 3-fold) compared with genetically induced hyperactivation (6- to 8-fold) that has been associated with pathological etiologies of mTORC1 hyperaction (e.g., development of TSC (47).”
From Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation (2019) · cites this paper as [47]
In the citing paper
“While it is true that the chronic hyperactivation of mTORC1 induced either genetically or through natural mutations (e.g., TSC1/2 inactivation) has been associated with the development and/or propagation of certain cancers, this is quite different from the observed effects of NV-5138 on mTORC1 activation in the current context.”
From Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation (2019) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 4×
“Acknowledgments We thank Giulia Scotti and Ivan Molineris at the Centre for Translational Genomics and Bioinformatics, Ospedale San Raffaele, for RNA-Seq data processing, GSEA, and meta-analysis.”
MethodInfluentialProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“Thus, the superior efficacy of rapamycin treatment on the growth of mouse SEGAs in comparison with the dual PI3K-mTOR kinase inhibitor PI-103 as described in our study might relate to the observation that prolonged rapamycin treatment strongly impairs Akt signaling by very efficiently interfering with the assembly of…”
BackgroundCuratolo, P., Bombardieri, R., & Jozwiak, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61279-9 · Cited by 1,088
Gritti, A., Parati, E., Cova, L., Frolichsthal, P., Galli, R., Wanke, E., Faravelli, L., Morassutti, D., Roisen, F., Nickel, D., et al. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-03-01091.1996 · Cited by 1,030
Self-citationNeural stem cells and neurospheres—re-evaluating the relationship
Reynolds, B. A., & Rietze, R. L. (2005) · Nature Methods · doi:10.1038/nmeth758 · Cited by 673 · cited 3×
“Isolation and characterization of pNSCs from control and mutant TPN mice. pNSC cultures were established by neurosphere assay (NSA) (38) under mildly hypoxic (5% O2) culture conditions from the SVZ of adult control and mutant P10 and P15–17 TPN mice.”
BackgroundInfluentialA Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 1×
“Given that we did not find any mutation in PTEN or in proteins interacting with it in human SENs/SEGA, other genetic events might be responsible for the negative-feedback loop inactivity and/ or for the increase in Akt signaling in human lesions, such as those recently described that lead to activation of the PI3K/AKT…”
BackgroundA dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585 · cited 1×
“into nude mice, and, when tumor volume reached 10–20 mm3 42 days after transplant, animals were randomized and treated for 5 days a week with either rapamycin (6 mg/kg) or the dual PI3K-mTOR inhibitor PI-103 (5 mg/kg) (22) up to 4 weeks.”
MethodThe Adult Ventricular–Subventricular Zone (V-SVZ) and Olfactory Bulb (OB) Neurogenesis
Lim, D. A., & Alvarez-Buylla, A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018820 · Cited by 571 · cited 1×
“Patients’ SENs and SEGAs arise in the SVZ, which surrounds the lateral ventricles and comprises NSCs that persist postnatally (16).”
BackgroundThe TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511 · cited 1×
“Loss of the Tsc1-Tsc2 complex is known to attenuate mTORC2 activation, independent of Rheb and of the mTORC1-dependent negative feedback on Akt (27).”
BackgroundInduction of Expansion and Folding in Human Cerebral Organoids
Li, Y., Muffat, J., Omer, A., Bosch, I., Lancaster, M. A., Sur, M., Gehrke, L., Knoblich, J. A., & Jaenisch, R. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2016.11.017 · Cited by 436 · cited 1×
“Accordingly, AKT hyperactivation through PTEN loss has been recently shown to promote cell cycle reentry and to delay neuronal differentiation in human neural progenitors (23).”
BackgroundDynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2
Humphrey, S. J., Yang, G., Yang, P., Fazakerley, D. J., Stöckli, J., Yang, J. Y., & James, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.010 · Cited by 411 · cited 1×
“Indeed, it has been recently shown that, in a variety of tissue-specific cell lines, AktT308 may work as an upstream activator of mTORC2 by phosphorylating mSin1T86 (28, 29).”
BackgroundPtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase Complex
Liu, P., Gan, W., Chin, Y. R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L. C., Toker, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0460 · Cited by 382 · cited 1×
“were used for Vectastain Elite ABC development and Dako EnVithrough Pten loss may also activate mTORC2 by releasing SIN1-PH inhibition (30).”
MethodThe mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368 · cited 4×
“PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex.”
BackgroundInfluentialA Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Yang, G., Murashige, D. S., Humphrey, S. J., & James, D. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.016 · Cited by 295 · cited 6×
“Indeed, it has been recently shown that, in a variety of tissue-specific cell lines, AktT308 may work as an upstream activator of mTORC2 by phosphorylating mSin1T86 (28, 29).”
BackgroundInfluentialmTOR: A pathogenic signaling pathway in developmental brain malformations
Crino, P. B. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.07.008 · Cited by 266 · cited 3×
“PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex.”
BackgroundMagri, L., Cambiaghi, M., Cominelli, M., Alfaro-Cervello, C., Cursi, M., Pala, M., Bulfone, A., Garcìa-Verdugo, J. M., Leocani, L., Minicucci, F., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.09.008 · Cited by 256 · cited 6×
“Notably, Gpnmb, one of the 10 top-ranking upregulated genes in mouse SEGAs (Figure 10C), was confirmed as being overexpressed more than 200 times in mouse SEGAs over control pNSCs by quantitative PCR analysis (Figure 10C).”
BackgroundMethodInfluentialSelf-citationThe genomic landscape of tuberous sclerosis complex
Martin, K. R., Zhou, W., Bowman, M. J., Shih, J., Au, K. S., Dittenhafer-Reed, K. E., Sisson, K. A., Koeman, J., Weisenberger, D. J., Cottingham, S. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15816 · Cited by 238 · cited 5×
“Next, to further test the degree of molecular commonality between mouse and human brain lesions, we exploited mutational data derived from human SEN/SEGA specimens (20) and assessed whether somatic mutations could be retrieved in the human PTEN locus or in protein known to interact with PTEN (21).”
BackgroundMethodInfluentialFeedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2
Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D., Kwiatkowski, D. J., & Cantley, L. C. (2005) · Genes & Development · doi:10.1101/gad.1314605 · Cited by 235 · cited 1×
“To enhance Akt activation, we took advantage of a strategy relying on the inactivation of Pten, the major negative regulator of PI3K activation, which promotes cell proliferation and growth (14).”
MethodLoss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse
Way, S. W., McKenna, J., Mietzsch, U., Reith, R. M., Wu, H. C.-J., & Gambello, M. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp025 · Cited by 213 · cited 3×
“PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex.”
BackgroundTemporal regulation of Cre recombinase activity in neural stem cells
Imayoshi, I., Ohtsuka, T., Metzger, D., Chambon, P., & Kageyama, R. (2006) · genesis · doi:10.1002/dvg.20212 · Cited by 207 · cited 2×
“(TPN) mutant mice, mixed-background (129S4/SvJae, C57BL/6) Tsc1ccPtencc mice (both from The Jackson Laboratory) were intercrossed with Nestin-CreERT2 heterozygous mice (17).”
BackgroundMethodEverolimus for subependymal giant cell astrocytoma: 5‐year final analysis
Franz, D. N., Agricola, K., Mays, M., Tudor, C., Care, M. M., Holland‐Bouley, K., Berkowitz, N., Miao, S., Peyrard, S., & Krueger, D. A. (2015) · Annals of Neurology · doi:10.1002/ana.24523 · Cited by 173 · cited 1×
“Thus, in agreement with results from recent clinical trials (34, 35), chronic treatment with rapalogs alone seems to be sufficient for significantly reducing the burden of brain-associated TSC lesions as SEGAs.”
ResultNeuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin
Carson, R. P., Van Nielen, D. L., Winzenburger, P. A., & Ess, K. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.024 · Cited by 165
Peretto, P., Giachino, C., Aimar, P., Fasolo, A., & Bonfanti, L. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20576 · Cited by 162 · cited 2×
“We selected different time windows of nestin-driven Cre recombination, which included distinct stages of development of the postnatal SVZ, characterized by different features and involving several types of progenitors (24).”
BackgroundMethodGenetics of tuberous sclerosis complex: implications for clinical practice
Caban, C., Khan, N., Hasbani, D., & Crino, P. B. (2016) · The Application of Clinical Genetics · doi:10.2147/tacg.s90262 · Cited by 131
Costa, V., Aigner, S., Vukcevic, M., Sauter, E., Behr, K., Ebeling, M., Dunkley, T., Friedlein, A., Zoffmann, S., Meyer, C. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.090 · Cited by 119 · cited 1×
“org Volume 128 Number 4 April 2018 reproduce the neurological defects seen in TSC (36, 37).”
Zhou, J., Shrikhande, G., Xu, J., McKay, R. M., Burns, D. K., Johnson, J. E., & Parada, L. F. (2011) · Genes & Development · doi:10.1101/gad.16750211 · Cited by 113 · cited 5×
“Ectopic bulb-like ventral structures, located in the proximity of the interventricular foramen and similar to those described in single Tsc1c/c Nestin-CreERT2+ mice (7, 11) and Ptenc/c Nestin-CreERT2+ mice (15), were also found (Supplemental Figure 2A).”
BackgroundMethodInfluentialTyburczy, M. E., Kotulska, K., Pokarowski, P., Mieczkowski, J., Kucharska, J., Grajkowska, W., Roszkowski, M., Jóźwiak, S., & Kaminska, B. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090950 · Cited by 88 · cited 3×
“Interestingly, many genes that were upregulated in pNSC-derived mouse SEGAs versus control pNSCs (with log2 fold change ranging from 5 to 8) (Figure 10C) were highly expressed also in the corresponding human TSC lesions, e.g., Gpnmb (6, 19, 20), Mpeg1 (20), Ltf, and Sln (19) (Supplemental Table 5 and Supplemental Figu…”
BackgroundMalaney, P., Pathak, R. R., Xue, B., Uversky, V. N., & Davé, V. (2013) · Scientific Reports · doi:10.1038/srep02035 · Cited by 79 · cited 6×
“Zhu G, et al. PTEN signaling in the postnatal perivascular progenitor niche drives medulloblastoma formation.”
BackgroundInfluentialFeliciano, D. M., Quon, J. L., Su, T., Taylor, M. M., & Bordey, A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr511 · Cited by 78 · cited 3×
“We set out to exploit the same gene inactivation strategy described in seminal prior publications (7, 11, 15), i.”
BackgroundMethodInducible site‐specific recombination in neural stem/progenitor cells
Chen, J., Kwon, C., Lin, L., Li, Y., & Parada, L. F. (2009) · genesis · doi:10.1002/dvg.20465 · Cited by 72 · cited 1×
“Indeed, nestin expression in cerebellar NSCs persists up to 4 postnatal weeks (25).”
BackgroundPollizzi, K. N., Malinowska-Kołodziej, I., Stumm, M., Lane, H. A., & Kwiatkowski, D. J. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-38 · Cited by 72 · cited 2×
“In model systems displaying mTOR hyperactivation by deletion of Tsc1 only, different studies described the effect of the combined inhibition of mTOR and Akt by either coadministration of rapamycin with a single Akt inhibitor (31), or delivery of a dual PI3K-mTOR inhibitor (32).”
BackgroundResultLi, Y., Cao, J., Chen, M., Li, J., Sun, Y., Zhang, Y., Zhu, Y., Wang, L., & Zhang, C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.020 · Cited by 62 · cited 1×
“org Volume 128 Number 4 April 2018 reproduce the neurological defects seen in TSC (36, 37).”
mTOR signaling in neural stem cells: from basic biology to disease
Magri, L., & Galli, R. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1196-x · Cited by 52 · cited 2×
“To this end, we exploited a combined deletion strategy, by which we ablated in pNSCs not only the TSC disease gene Tsc1, as previously performed by different groups (10), but also the tumor suppressor Pten.”
MethodResultSelf-citationTiming of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
Magri, L., Cominelli, M., Cambiaghi, M., Cursi, M., Leocani, L., Minicucci, F., Poliani, P. L., & Galli, R. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.012096 · Cited by 51
Self-citationZhu, G., Chow, L. M. L., Bayazitov, I. T., Tong, Y., Gilbertson, R. J., Zakharenko, S. S., Solecki, D. J., & Baker, S. J. (2012) · Development · doi:10.1242/dev.083154 · Cited by 46
Trelińska, J., Dachowska, I., Barańska, D., Stawiski, K., Kotulska, K., Fendler, W. M., Jóźwiak, S., & Mlynarski, W. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26347 · Cited by 27 · cited 1×
“Thus, in agreement with results from recent clinical trials (34, 35), chronic treatment with rapalogs alone seems to be sufficient for significantly reducing the burden of brain-associated TSC lesions as SEGAs.”
ResultJi, S., Lin, W., Wang, L., Ni, Z., Jin, F., Zha, X., & Fei, G. (2017) · Journal of Cancer · doi:10.7150/jca.17205 · Cited by 24
Brain tumor formation in tuberous sclerosis depends on erk activation
Jóźwiak, J., Grajkowska, W., Kotulska, K., Jóźwiak, S., Zalewski, W., Zajączkowska, A., Roszkowski, M., Słupianek, A., & Wlodarski, P. K. (2007) · NeuroMolecular Medicine · doi:10.1007/bf02685886 · Cited by 22 · cited 15×
“To test whether Tsc1 and Pten loss of function in this compartment might lead to the development of the perivenknowledge, closely resembled human SENs and SEGAs, in terms of histology, cellular composition, and molecular pattern.”
BackgroundInfluentialPTEN Signaling in the Postnatal Perivascular Progenitor Niche Drives Medulloblastoma Formation
Zhu, G. G., Rankin, S. L., Larson, J. D., Zhu, X., Chow, L. M. L., Qu, C., Zhang, J., Ellison, D. W., & Baker, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1991 · Cited by 18 · cited 1×
“Mutant mice eventually died 37–45 days after birth (Supplemental Figure 1B), likely as a consequence of cerebellar defects due to Tsc1/Pten inactivation in nestin-expressing progenitor cells found in the early-postnatal cerebellum (Supplemental Figure 1A) (18).”
BackgroundSiedlecka, M., Szlufik, S., Grajkowska, W., Roszkowski, M., & Jóźwiak, J. (2015) · Folia Neuropathologica · doi:10.5114/fn.2015.49969 · Cited by 13
Cited by
Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming
Bénéchet, A. P., De Simone, G., Di Lucia, P., Cilenti, F., Barbiera, G., Le Bert, N., Fumagalli, V., Lusito, E., Moalli, F., Bianchessi, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1620-6 · Cited by 222
Self-citationRole of mTOR Complexes in Neurogenesis
LiCausi, F., & Hartman, N. W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051544 · Cited by 165
De Simone, G., Andreata, F., Bleriot, C., Fumagalli, V., Laura, C., Garcia-Manteiga, J. M., Di Lucia, P., Gilotto, S., Ficht, X., De Ponti, F. F., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.005 · Cited by 154
Self-citationSestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126859 · Cited by 88
The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
Feliciano, D. M. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00039 · Cited by 69
“Moreover, this same group did not find evidence that PTEN is mutated in SEGAs (Zordan et al., 2018).”
BackgroundInfluential
Metadata
- Authors
- Zordan, P., Cominelli, M., Cascino, F., Tratta, E., Poliani, P. L., & Galli, R.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- University of Brescia (IT)
- Corresponding author
- Galli, Rossella
- Venue
- Journal of Clinical Investigation
- Published
- 2018-03-12
- Volume
- 128
- Issue
- 4
- Pages
- 1688-1706
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5873854
- OpenAlex
- W2787744028
- Cited by
- 28
- References
- 40
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 3
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon (GGP13022)
- Associazione Sclerosi Tuberosa Italia (n/a)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- tuberous sclerosis complex, mTORC1, Akt, mTORC2, subependymal giant cell astrocytoma, subependymal nodules, neural stem cells, TSC1, PTEN, rapamycin, tumor progression, hamartoma, mouse model
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Astrocytoma, Brain Neoplasms, Mice, Transgenic, Tuberous Sclerosis, Proto-Oncogene Proteins c-akt, Mice, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.